Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT03172624
Phase
PHASE2
Status
Completed

Conditions

  • Salivary Gland Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    nivolumab 3 mg/kg every 2 weeks
  • Ipilimumab — DRUG
    ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)

Study Details

The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.

Key Dates

Start date
May 26, 2017
Status verified
Dec 2024
Primary completion
Dec 18, 2024
Completion
Dec 18, 2024

Study Design

Enrollment
64 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: R/M adenoid cystic carcinoma (ACC)
    Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
  • Experimental: R/M SGC of any histology, except ACC (Non ACC)
    Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).

Primary Outcome Measure

Best Overall Response Rate [ Time Frame: 2 years ]

Locations (8)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Basking RidgeBasking RidgeNew Jersey07920-
Memorial Sloan Kettering MonmouthMiddletownNew Jersey07748-
Memorial Sloan Kettering BergenMontvaleNew Jersey07645-
Memorial Sloan Kettering CommackCommackNew York11725-
Memorial Sloan Kettering WestchesterHarrisonNew York10604-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
Memorial Sloan Kettering Rockville CentreRockville CentreNew York11570-
Memorial Sloan Kettering NassauUniondaleNew York11553-

Related coverage on Hipa.ai

Find similar trials in Basking Ridge, NJ

Related Studies